EICHOR
● Recruiting
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Condition: Gastric Cancer · Colon Cancer · Rectal Cancer · Sponsor: Chongqing Precision Biotech Co., Ltd
About this study
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
This description comes directly from the study's public registry record.
Talk to the study team
Qi Mei, M.D · 15871708675 · borismq@hotmail.com
Shuang Wei, M.D · 18062087116 · wsdavid2001@163.com
Always discuss trial participation with your own doctor first.
Locations (3)
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06006390